Navigation Links
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/26/2008

ner Professor of Psychiatry and Neuroscience at Baylor College of Medicine, and Dr. Richard Rawson of the University of California, Los Angeles' Department of Psychiatry. Drs. Kosten and Rawson are both key opinion leaders in the field of substance abuse and are contributing greatly to the achievement of Catalyst's goals."

"We are especially pleased that the positive results from our Mexico trial were discussed in Newsweek magazine's cover article on addiction in the March 3, 2008 issue. In the article, one of the foremost experts in the field of addiction noted that the results of this trial provide the best efficacy signal of any trial conducted so far for cocaine treatment and that treatment with vigabatrin seems especially promising, even for patients that are hardest to treat -- long-term cocaine addicts. We believe strongly in the viability of our technology and the promise that treatment with CPP-109 may bring to patients, the healthcare system and society at large."

Financial Results

For the year ended December 31, 2007, the Company's net loss was $4,139,493, or $0.33 per basic and diluted share, compared to a net loss of $2,729,454, or $0.36 per basic and diluted share, in the prior year. Results for 2007 and 2006 include non-cash charges relating to stock-based compensation of $556,343 and $1,220,739, respectively.

Research and development expenses for 2007 were $2,990,659, compared to $1,087,144 in 2006. This includes non-cash stock-based compensation for 2007 and 2006 of $365,107 and $344,649, respectively.

General and administrative expenses for 2007 were $2,036,470, compared to $1,815,183 in 2006. This includes non-cash stock-based compensation for 2007 and 2006 of $191,236 and $876,090, respectively.

For the fourth quarter of 2007, the Company's net loss was $944,938, or $0.08 per basic and diluted share, compared to a net loss of $741,241, or $0.07 per basic and diluted share, for the same period in 2006. Res
'/>"/>

SOURCE Catalyst Pharmaceutical Partners
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- The U.S. Department of Health and Human Services (HHS) ... Case Medical Center Seidman Cancer Center totaling $4.7 million ... care for patients with complex cancer. ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... levels following 4 weeks of, treatment with R7128 1500mg and Pegasys(R) plus ... tolerability comparable to ... - Conference Call Scheduled for 4:00PM ET Today -, PRINCETON, N.J., ... of a 4-week Phase 1,clinical trial to evaluate two oral dose levels ...
... Duration of ... Neutropenia- ... Jan. 7 Maxygen, Inc.,(Nasdaq: MAXY ) today announced positive progress in ... the trial include the following:, -- Patients in the initial 10 ...
Cached Medicine Technology:Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 2Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 3Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 5Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 6Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 2Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 3Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 4
(Date:7/11/2014)... UC San Francisco shows that an "expressive therapy" ... women living with HIV disclose their health status ... safety and quality of their relationships., "Medication alone ... Edward L. Machtinger, MD, director of the Women,s ... our patients are on effective antiretroviral therapy but ...
(Date:7/11/2014)... July 11, 2014 Bedros Keuilian is known ... title he’s earned by founding the fast-selling fitness franchise in ... their businesses. He works with successful boot camp owners on ... on the traits of the most successful boot camp owners ... important qualities. , “I’ve worked with and coached some of ...
(Date:7/11/2014)... When the mercury rises, heat can strain the ... heart, takes on a heavier load in hot weather to ... of the Harvard Men's Health Watch . , For ... than knowing their limits and drinking enough fluids. But what ... more sensitive to the heat," says Dr. Joanne Foody, Director ...
(Date:7/11/2014)... 11, 2014 As reported by Forbes ... Cocaine: Are Genetics To Blame (6/30), Indino Downey has ... and paraphernalia to smoke it with. His father, well-known ... his son inherited from him may have something to ... the news during the 1980s and 1990s for substance ...
(Date:7/11/2014)... Timex, the leader in outdoor and sports performance ... Network, the brand’s new online content portal which will ... and special product offers for consumers. , The ... the Timex IRONMAN watch brand and will serve as ... The hub will reflect the active lifestyle of Timex ...
Breaking Medicine News(10 mins):Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 3Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 2Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 3Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Timex Announces Launch of Timex Performance Network 2
... All PETCO stores nationwide will host a free pet nutrition, ... experts on Saturday, November 14 at 2 p.m. During the 30-minute, ... the nutritional needs of, their dogs ... good pet nutrition, receive an assessment of their individual, ...
... the University of Florida Proton Therapy Institute have formed a ... announcement follows the approval of the first clinical study to ... in children younger than 3 years old. ... receive proton therapy at the UF Proton Therapy Institute in ...
... issue of European Urology , the official journal ... entitled ,Are Infertile Men Less Healthy than Fertile Men? ... Salonia et al. The conclusion is that male factor ... as objectively scored with the hospital-based Charlson Comorbidity Index. ...
... In the construction industry, respiratory disease, often leading to ... major public health concern. Studies led by Deborah ... Construction, have shown that specific types of sanding tools ... these health hazards, yet the industry,s usage of the ...
... The first human embryonic stem cell treatment approved by ... limb function in rats with neck spinal cord injuries ... people with cervical damage. In January, the U.S. Food ... permission to test the UC Irvine treatment in individuals with ...
... ACCRA, Ghana -- The lives of almost 4 million ... saved every year if well-established, affordable health care interventions ... report by the national science academies of seven African ... knowledge to save lives, says the report, which calls ...
Cached Medicine News:Health News:St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial 2Health News:European Urology: Male factor infertility associated with comorbidities 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 3Health News:UCI embryonic stem cell therapy restores walking ability in rats with neck injuries 2Health News:Using science to save lives of mothers and children in Africa 2Health News:Using science to save lives of mothers and children in Africa 3Health News:Using science to save lives of mothers and children in Africa 4
... Plate is a semi-rigid system intended ... The Slim-LOC is based on the ... current market technology. The Slim-LOCTM system ... instrumentation. Reduced width (16 mm), low ...
... SC-Acufix anterior cervical plate system is a ... integrated swivel, which provides for consistent, reliable ... bone screw disengagement or backout. This innovative ... locking screw. Simply implant your screws and ...
... a leading provider of telemedicine solutions. ... state-of-the-art technology deliver accurate, reliable and ... professionals and clients in improving outcomes. ... ECG technology to gather patient data, ...
... is a high performance temperature controlled shaker ... shaking speed and incubation time are fully ... parameters are displayed on the LCD in ... below the microplates provide uniform incubation with ...
Medicine Products: